<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01085344</url>
  </required_header>
  <id_info>
    <org_study_id>0019970022</org_study_id>
    <nct_id>NCT01085344</nct_id>
  </id_info>
  <brief_title>Canadian Hemophilia Prophylaxis Study</brief_title>
  <acronym>CHPS</acronym>
  <official_title>Moderate Term Musculoskeletal Outcomes With Escalating Dose Prophylaxis: the Canadian Hemophilia Prophylaxis Study Follow-up Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Hospital for Sick Children</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Hospital for Sick Children</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary prophylaxis given less frequently initially, with the infusion frequency increased if
      needed (Escalating Dose Prophylaxis), is likely to be less expensive and associated with
      fewer complications than standard prophylaxis while reducing disability to a greater degree
      than intermittent therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There are 2 specific study objectives. The first is to estimate the incidence of target joint
      bleeding in patients with severe hemophilia A treated (for primary prophylaxis) with
      Escalating Dose Prophylactic factor replacement. The second objective is to obtain accurate
      estimates of the direct and indirect costs associated with this protocol for use in a
      cost-effectiveness model (comparing Escalating Dose with standard prophylaxis and with
      intermittent therapy).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 26, 1997</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Who Developed Target Joint Bleeding</measure>
    <time_frame>6 months</time_frame>
    <description>The number of participants who developed target joint bleeding during the study, which was defined as 3 bleeds into any 1 joint within a period of 3 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Annualized Bleeding Rate</measure>
    <time_frame>6 months</time_frame>
    <description>Number of index hemarthorses (bleeds into ankles, elbows or knees) per patient per year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annualized Factor Use</measure>
    <time_frame>12 months</time_frame>
    <description>annual factor usage per subject</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Who Developed an Inhibitor to FVIII</measure>
    <time_frame>6 months</time_frame>
    <description>The number of patients who developed an inhibitor for FVIII, defined as &gt;= 0.5 Bethesda Units</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical Disability as Measured by the CHAQ</measure>
    <time_frame>through study completion, a median of 10 years</time_frame>
    <description>complete the Child Health Assessment Questionnaire (CHAQ) at each 6 month visit. The CHAQ is a validated tool to measure a disability index, with a possible score range of 0-3, where 0 represents no disability and 3 represents maximal disability. The CHAQ is known to have a strong ceiling effect.
The CHAQ was collected at each study visit (i.e. every 6 months for the duration each patient was on study). The reported score represents the median end of study score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Joint Damage as Determined by the Physiotherapy Score</measure>
    <time_frame>through study completion, a median of 10 years</time_frame>
    <description>Complete the modified Colarado Physiotherapy Assessment every 6 months at each visit with a score range 0-30 for ankles and knees and 0-26 for elbows), measured at all study visits, which we modified by not assessing crepitus or the ankle joint circumference measurement. For each scale, 0 represents no joint damage, with 26/30 representing maximum possible joint damage. The reported score represents the median end of study score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications Arising From Indwelling Venous Catheter</measure>
    <time_frame>6 months</time_frame>
    <description>collect information on any complications relating to indwelling venous catheters that some subject use.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Severe Hemophilia A</condition>
  <arm_group>
    <arm_group_label>Factor VIII</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>escalating dose Factor VIII</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Recombinant Factor VIII (Advate/Helixate FS/KoegenateFS)</intervention_name>
    <description>escalating dose prophylaxis</description>
    <arm_group_label>Factor VIII</arm_group_label>
    <other_name>Recombinant Factor VIII (antihemophilic agent)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Recombinant Factor VIII (Advate/Helixate FS/KoegenateFS)</intervention_name>
    <description>escalating dose</description>
    <arm_group_label>Factor VIII</arm_group_label>
    <other_name>recombinant factor VIII (antihemophilic agent)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Severe hemophilia A (factor level less than 2%).

          -  Age greater than 1 year and less than or equal to 2.5 years.

          -  Normal joints using the World Federation of Hemophilia orthopedic scale.

          -  Normal radiographs of joints in which bleeding has occurred using the World Federation
             of Hemophilia radiographic scale.

          -  Platelet count of &gt; 150,000.

          -  Informed consent to participate.

        Exclusion Criteria:

          -  Three or more clinically determined bleeds into any single elbow, knee or ankle.

          -  Presence or past history of a circulating inhibitor (level â‰¥ 0.5 Bethesda Units).

          -  Family judged to be non-compliant by the local hemophilia clinic director.

          -  Competing risk (symptomatic HIV infection, juvenile rheumatoid arthritis, metabolic
             bone disease, or other diseases known to cause or mimic arthritis.)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>30 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brian M Feldman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Hospital for Sick Children</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>March 1, 2010</study_first_submitted>
  <study_first_submitted_qc>March 10, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 11, 2010</study_first_posted>
  <results_first_submitted>May 10, 2018</results_first_submitted>
  <results_first_submitted_qc>November 18, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">December 5, 2019</results_first_posted>
  <last_update_submitted>November 18, 2019</last_update_submitted>
  <last_update_submitted_qc>November 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Hospital for Sick Children</investigator_affiliation>
    <investigator_full_name>Brian Feldman</investigator_full_name>
    <investigator_title>Division Head, Rheumatology</investigator_title>
  </responsible_party>
  <keyword>hemophilia, prophylaxis, cost effectiveness</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Factor VIII</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Between June 26, 1997, and Jan 30, 2007, 56 boys were enrolled from 12 Canadian centres.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Factor VIII</title>
          <description>escalating dose Factor VIII
Recombinant Factor VIII (Advate/Helixate FS/KoegenateFS): escalating dose prophylaxis
Recombinant Factor VIII (Advate/Helixate FS/KoegenateFS): escalating dose</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="56"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Factor VIII</title>
          <description>escalating dose Factor VIII
Recombinant Factor VIII (Advate/Helixate FS/KoegenateFS): escalating dose prophylaxis
Recombinant Factor VIII (Advate/Helixate FS/KoegenateFS): escalating dose</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="56"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.6" lower_limit="1.2" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race or Ethnic Group</title>
              <category_list>
                <category>
                  <title>White European</title>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mixed Aboriginal-Canadian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mixed Latin-American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>African Heritage</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Middle Eastern</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Developed Target Joint Bleeding</title>
        <description>The number of participants who developed target joint bleeding during the study, which was defined as 3 bleeds into any 1 joint within a period of 3 months.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Factor VIII</title>
            <description>escalating dose Factor VIII
Recombinant Factor VIII (Advate/Helixate FS/KoegenateFS): escalating dose prophylaxis
Recombinant Factor VIII (Advate/Helixate FS/KoegenateFS): escalating dose</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Developed Target Joint Bleeding</title>
          <description>The number of participants who developed target joint bleeding during the study, which was defined as 3 bleeds into any 1 joint within a period of 3 months.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Annualized Bleeding Rate</title>
        <description>Number of index hemarthorses (bleeds into ankles, elbows or knees) per patient per year</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Factor VIII</title>
            <description>escalating dose Factor VIII
Recombinant Factor VIII (Advate/Helixate FS/KoegenateFS): escalating dose prophylaxis
Recombinant Factor VIII (Advate/Helixate FS/KoegenateFS): escalating dose</description>
          </group>
        </group_list>
        <measure>
          <title>Annualized Bleeding Rate</title>
          <description>Number of index hemarthorses (bleeds into ankles, elbows or knees) per patient per year</description>
          <units>episodes per participant per year</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.95" lower_limit="0.44" upper_limit="1.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Annualized Factor Use</title>
        <description>annual factor usage per subject</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Factor VIII</title>
            <description>escalating dose Factor VIII
Recombinant Factor VIII (Advate/Helixate FS/KoegenateFS): escalating dose prophylaxis
Recombinant Factor VIII (Advate/Helixate FS/KoegenateFS): escalating dose</description>
          </group>
        </group_list>
        <measure>
          <title>Annualized Factor Use</title>
          <description>annual factor usage per subject</description>
          <units>IU/kg/year</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3600" lower_limit="3200" upper_limit="4700"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Who Developed an Inhibitor to FVIII</title>
        <description>The number of patients who developed an inhibitor for FVIII, defined as &gt;= 0.5 Bethesda Units</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Factor VIII</title>
            <description>escalating dose Factor VIII
Recombinant Factor VIII (Advate/Helixate FS/KoegenateFS): escalating dose prophylaxis
Recombinant Factor VIII (Advate/Helixate FS/KoegenateFS): escalating dose</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Who Developed an Inhibitor to FVIII</title>
          <description>The number of patients who developed an inhibitor for FVIII, defined as &gt;= 0.5 Bethesda Units</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Physical Disability as Measured by the CHAQ</title>
        <description>complete the Child Health Assessment Questionnaire (CHAQ) at each 6 month visit. The CHAQ is a validated tool to measure a disability index, with a possible score range of 0-3, where 0 represents no disability and 3 represents maximal disability. The CHAQ is known to have a strong ceiling effect.
The CHAQ was collected at each study visit (i.e. every 6 months for the duration each patient was on study). The reported score represents the median end of study score.</description>
        <time_frame>through study completion, a median of 10 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Factor VIII</title>
            <description>escalating dose Factor VIII
Recombinant Factor VIII (Advate/Helixate FS/KoegenateFS): escalating dose prophylaxis
Recombinant Factor VIII (Advate/Helixate FS/KoegenateFS): escalating dose</description>
          </group>
        </group_list>
        <measure>
          <title>Physical Disability as Measured by the CHAQ</title>
          <description>complete the Child Health Assessment Questionnaire (CHAQ) at each 6 month visit. The CHAQ is a validated tool to measure a disability index, with a possible score range of 0-3, where 0 represents no disability and 3 represents maximal disability. The CHAQ is known to have a strong ceiling effect.
The CHAQ was collected at each study visit (i.e. every 6 months for the duration each patient was on study). The reported score represents the median end of study score.</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Joint Damage as Determined by the Physiotherapy Score</title>
        <description>Complete the modified Colarado Physiotherapy Assessment every 6 months at each visit with a score range 0-30 for ankles and knees and 0-26 for elbows), measured at all study visits, which we modified by not assessing crepitus or the ankle joint circumference measurement. For each scale, 0 represents no joint damage, with 26/30 representing maximum possible joint damage. The reported score represents the median end of study score</description>
        <time_frame>through study completion, a median of 10 years</time_frame>
        <population>Median CCPES Score at study-end</population>
        <group_list>
          <group group_id="O1">
            <title>Factor VIII</title>
            <description>escalating dose Factor VIII
Recombinant Factor VIII (Advate/Helixate FS/KoegenateFS): escalating dose prophylaxis
Recombinant Factor VIII (Advate/Helixate FS/KoegenateFS): escalating dose</description>
          </group>
        </group_list>
        <measure>
          <title>Joint Damage as Determined by the Physiotherapy Score</title>
          <description>Complete the modified Colarado Physiotherapy Assessment every 6 months at each visit with a score range 0-30 for ankles and knees and 0-26 for elbows), measured at all study visits, which we modified by not assessing crepitus or the ankle joint circumference measurement. For each scale, 0 represents no joint damage, with 26/30 representing maximum possible joint damage. The reported score represents the median end of study score</description>
          <population>Median CCPES Score at study-end</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Left Ankle</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="0" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right Ankle</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="0" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left Elbow</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right Elbow</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left Knee</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right Knee</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Complications Arising From Indwelling Venous Catheter</title>
        <description>collect information on any complications relating to indwelling venous catheters that some subject use.</description>
        <time_frame>6 months</time_frame>
        <population>25 participants had a central venous access device (CVAD) during the study</population>
        <group_list>
          <group group_id="O1">
            <title>Factor VIII</title>
            <description>escalating dose Factor VIII
Recombinant Factor VIII (Advate/Helixate FS/KoegenateFS): escalating dose prophylaxis
Recombinant Factor VIII (Advate/Helixate FS/KoegenateFS): escalating dose</description>
          </group>
        </group_list>
        <measure>
          <title>Complications Arising From Indwelling Venous Catheter</title>
          <description>collect information on any complications relating to indwelling venous catheters that some subject use.</description>
          <population>25 participants had a central venous access device (CVAD) during the study</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Factor VIII</title>
          <description>escalating dose Factor VIII
Recombinant Factor VIII (Advate/Helixate FS/KoegenateFS): escalating dose prophylaxis
Recombinant Factor VIII (Advate/Helixate FS/KoegenateFS): escalating dose</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Brian Feldman</name_or_title>
      <organization>The Hospital for Sick Children</organization>
      <phone>416-813-5828</phone>
      <email>brian.feldman@sickkids.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

